(RTTNews) - Amgen (AMGN) announced the FDA has broadened the approved use of Repatha or evolocumab to include adults at increased risk for major adverse cardiovascular events due to uncontrolled ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...
Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha ...
Most commercial insurance plans and Medicare Part D plans cover Repatha, and Medicare Advantage (Part C) plans with drug coverage may also cover it. To find out if your Medicare Advantage or Part D ...
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE ...
AbbVie’s Qulipta (atogepant tablets) has been approved for the preventive treatment of episodic migraine in adults. In the pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled, ...
Amgen’s (AMGN) worst-case scenario from the outcomes trial of Repatha can be dismissed. The California-based group says the cholesterol-lowering jab reduced risk of heart attacks, strokes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results